{
    "name": "brolucizumab intravitreal",
    "comment": "Rx",
    "other_names": [
        "Beovu",
        "brolucizumab-dbll"
    ],
    "classes": [
        "Macular Degeneration Agents",
        "Ophthalmics",
        "VEGF Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/beovu-brolucizumab-intravitreal-1000350",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies in pregnant women",
            "Based on anti-VEGF mechanism of action, treatment may pose risk to human embryofetal development",
            "Use during pregnancy only if the potential benefit outweighs the potential fetal risk"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Intravitreal administration to pregnant monkeys once every 4 weeks in one eye from organogenesis to birth caused fetal loss and a structural abnormality (bilateral absent metatarsal) in offspring at 10-fold the maximum recommended human dose (MRHD) on mg/kg basis",
                    "VEGF inhibition has also been shown to affect follicular development, corpus luteum function, and fertility"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential should use highly effective contraception (methods that result in <1% pregnancy rates) during treatment and for at least 1 month after the last dose following brolucizumab discontinuation"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "No studies have been conducted and it is not known whether brolucizumab can affect reproductive capacity",
                    "Based on its anti-VEGF mechanism of action, treatment may pose a risk to reproductive capacity"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No data are available regarding the presence of brolucizumab in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production/excretion",
            "Because many drugs are transferred in human milk and because of the potential for absorption and adverse reactions in the breastfed child, breastfeeding is not recommended during treatment and for at least 1 month after the last dose following discontinuation"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Ocular or periocular infections",
                "Active intraocular inflammation",
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation",
                "Intravitreal injections are associated with endophthalmitis and retinal detachments; instruct patients to immediately report any symptoms suggestive of endophthalmitis or retinal detachment",
                "Acute increases in intraocular pressure (IOP) have been seen within 30 minutes of intravitreal injection; sustained IOP increases have also been reported; both IOP and perfusion of the optic nerve head must be monitored and managed appropriately",
                "A low rate of arterial thromboembolic events observed during clinical trials following intravitreal use of vascular endothelial growth factor (VEGF) inhibitors"
            ],
            "specific": [
                {
                    "type": "Retinal vasculitis",
                    "description": [
                        "Retinal vasculitis and/or retinal vascular occlusion, typically in presence of intraocular inflammation, reported with therapy",
                        "Retinal vasculitis and/or retinal vascular occlusion, typically in presence of intraocular inflammation, are immune-mediated adverse events related to exposure to the drug; this treatment-emergent antibody response may develop following the first intravitreal injection",
                        "The immune-mediated adverse events may occur following first intravitreal injection; discontinue treatment in patients who develop these events",
                        "Patients who experience intraocular inflammation following treatment may be at risk of developing retinal vasculitis and/or retinal vascular occlusion and should be closely monitored; patients should be instructed to report any change in vision without delay"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Blurred vision",
            "percent": "10"
        },
        {
            "name": "Cataract",
            "percent": "7"
        },
        {
            "name": "Conjunctival hemorrhage",
            "percent": "6"
        },
        {
            "name": "Vitreous floaters",
            "percent": "5"
        },
        {
            "name": "Eye pain",
            "percent": "5"
        },
        {
            "name": "Intraocular inflammation",
            "percent": "4"
        },
        {
            "name": "Intraocular pressure increased",
            "percent": "4"
        },
        {
            "name": "Retinal hemorrhage",
            "percent": "4"
        },
        {
            "name": "Vitreous detachment",
            "percent": "4"
        },
        {
            "name": "Conjunctivitis",
            "percent": "3"
        },
        {
            "name": "Retinal pigment epithelial tear",
            "percent": "3"
        },
        {
            "name": "Corneal abrasion",
            "percent": "2"
        },
        {
            "name": "Hypersensitivity",
            "percent": "2"
        },
        {
            "name": "Punctate keratitis",
            "percent": "1"
        },
        {
            "name": "Retinal tear",
            "percent": "1"
        },
        {
            "name": "Endophthalmitis",
            "percent": "1"
        },
        {
            "name": "Blindness",
            "percent": "1"
        },
        {
            "name": "Retinal artery occlusion",
            "percent": "1"
        },
        {
            "name": "Retinal detachment",
            "percent": "1"
        },
        {
            "name": "Conjunctival hyperemia",
            "percent": "1"
        },
        {
            "name": "Lacrimation increased",
            "percent": "1"
        },
        {
            "name": "Abnormal sensation in eye",
            "percent": "1"
        },
        {
            "name": "Detachment of retinal pigment epithelium",
            "percent": "1"
        },
        {
            "name": "Endophthalmitis and retinal detachment",
            "percent": null
        },
        {
            "name": "Retinal vasculitis and",
            "percent": null
        },
        {
            "name": "or retinal vascular occlusion",
            "percent": null
        },
        {
            "name": "Vitreous hemorrhage",
            "percent": null
        }
    ]
}